Neurocrine Biosciences, Inc. (NBIX): Price and Financial Metrics


Neurocrine Biosciences, Inc. (NBIX)

Today's Latest Price: $116.91 USD

1.91 (1.66%)

Updated Jan 22 4:00pm

Add NBIX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NBIX Stock Summary

  • With a price/earnings ratio of 115.04, Neurocrine Biosciences Inc P/E ratio is greater than that of about 91.48% of stocks in our set with positive earnings.
  • In terms of twelve month growth in earnings before interest and taxes, Neurocrine Biosciences Inc is reporting a growth rate of 134.56%; that's higher than 90.27% of US stocks.
  • As for revenue growth, note that NBIX's revenue has grown 54.24% over the past 12 months; that beats the revenue growth of 90.39% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Neurocrine Biosciences Inc, a group of peers worth examining would be IPGP, NOVT, CGNX, PTC, and MRCY.
  • Visit NBIX's SEC page to see the company's official filings. To visit the company's web site, go to www.neurocrine.com.

NBIX Stock Price Chart Interactive Chart >

Price chart for NBIX

NBIX Price/Volume Stats

Current price $116.91 52-week high $136.26
Prev. close $115.00 52-week low $72.14
Day low $114.08 Volume 647,900
Day high $117.71 Avg. volume 1,001,600
50-day MA $97.90 Dividend yield N/A
200-day MA $108.04 Market Cap 10.92B

Neurocrine Biosciences, Inc. (NBIX) Company Bio


Neurocrine Biosciences discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company was founded in 1992 and is based in San Diego, California.


NBIX Latest News Stream


Event/Time News Detail
Loading, please wait...

NBIX Latest Social Stream


Loading social stream, please wait...

View Full NBIX Social Stream

Latest NBIX News From Around the Web

Below are the latest news stories about Neurocrine Biosciences Inc that investors may wish to consider to help them evaluate NBIX as an investment opportunity.

Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report fourth quarter and year-end 2020 financial results after the Nasdaq market closes on Thursday, Feb. 4, 2021. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a company update that day at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Yahoo | January 20, 2021

Voyager Therapeutics: Complicated Story In Gene Therapy Development

Voyager Therapeutics (VYGR) was founded in 2013 and is still an early stage developer of gene therapies targeting neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial (and other partnered trials) for the treatment of Parkinson's disease. Other assets are preclinical....

Avisol Capital Partners on Seeking Alpha | January 18, 2021

Kevin Charles Gorman Sells 308,250 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kevin Charles Gorman sold 308,250 shares of Neurocrine Biosciences stock in a transaction that occurred on Friday, January 8th. The stock was sold at an average price of $110.22, for a total value of $33,975,315.00. Following the completion of the sale, the chief executive officer now owns 584,520 shares in […]

Watchlist News | January 14, 2021

Neurocrine Biosciences Shares Rise Despite Disappointing Q4 Earnings; Target Price $121

California-based biopharmaceutical company Neurocrine Biosciences reported worse-than-expected earnings in the fourth quarter as sales disappointed on anticipated inventory destocking; however, the shares rose over 7% on Friday.

Yahoo | January 8, 2021

Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today provided an update on its business performance, including preliminary net product and inventory adjusted sales results of INGREZZA® (valbenazine) for 2020, and key commercial and clinical development milestones for 2021. Kevin Gorman, Chief Executive Officer of Neurocrine Biosciences, will discuss these updates as part of a webcast presentation at the 39th Annual J.P. Morgan Healthcare Conference to be held virtually on Monday, January 11 at 2:00 p.m. Eastern Time, followed by a Question and Answer session at approximately 2:20 p.m. Eastern Time.

Yahoo | January 8, 2021

Read More 'NBIX' Stories Here

NBIX Price Returns

1-mo 19.70%
3-mo 18.08%
6-mo -7.21%
1-year 17.89%
3-year 31.76%
5-year 140.61%
YTD 21.97%
2020 -10.83%
2019 50.53%
2018 -7.96%
2017 100.49%
2016 -31.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.789 seconds.